Symbols

Symbols

Aime

Products

News

Markets

Watchlist

Brokers

News/

Stock/

LPCN

LPCN News

Newswire

09:40

Lipocine shares rise 12.67% intraday after positive interim safety data from Phase 3 PPD trial shows no major adverse events, DSMB recommends continuation.

02:21

Lipocine Advances Phase 3 Trial for Rapid PPD Treatment with No Serious Side Effects

02:09

Lipocine Reports Positive Interim Safety Data for LPCN 1154 in Postpartum Depression Trial

17:02

Lipocine shares surge 12.0% after hours on positive interim safety data from Phase 3 PPD trial.

09:51

Lipocine shares surge 11.67% intraday after positive interim safety review of Phase 3 PPD trial.

View More

About LPCN

Charts

--

Sector--

Established Date--

Listing Date--

Exchange--

Full-time Employees--

Fiscal Year Ends--

Website

Security Type--

Office address

Business

Introduction

View More